ArticleFrontiers in immunology2021
Integrated Profiling Identifies
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer.Nature communications · 2022Trial
- Recent research progress and clinical status of immunotherapy for colorectal cancer.Journal of advanced research · 2026Review
- Deciphering the role of acetylation-related gene NAT10 in colon cancer progression and immune evasion: implications for overcoming drug resistance.Discover oncology · 2025Article
- Integrative analysis regarding the correlation between collagen-related genes and prostate cancer.BMC cancer · 2024Article
- PLOD3 facilitated T cell activation in the colorectal tumor microenvironment and liver metastasis by the TNF-α/ NF-κB pathway.Journal of translational medicine · 2024Article
- Identification and validation of an ECM organization-related gene signature as a prognostic biomarker and therapeutic target for glioma patients.Genes & genomics · 2023Article
- Identification of PLOD3 and LRRN3 as potential biomarkers for Parkinson's disease based on integrative analysis.NPJ Parkinson's disease · 2023Article
- A hybrid deep forest-based method for predicting synergistic drug combinations.Cell reports methods · 2023Article
- Computational profiling and prognostic modeling based on lysosome-related genes in colorectal cancer.Frontiers in genetics · 2023Article
- Weighted gene co-expression network analysis combined with machine learning validation to identify key hub biomarkers in colorectal cancer.Functional & integrative genomics · 2022Article
- PLOD Family: A Novel Biomarker for Prognosis and Personalized Treatment in Soft Tissue Sarcoma.Genes · 2022Article
- A FeFrontiers in molecular biosciences · 2022Article
- The Underlying Roles of Exosome-Associated PIGR in Fatty Acid Metabolism and Immune Signaling in Colorectal Cancer.Journal of oncology · 2022Article
- Tumor-infiltrating immune cells based TMEscore and related gene signature is associated with the survival of CRC patients and response to fluoropyrimidine-based chemotherapy.Frontiers in oncology · 2022Article
- Computer classification and construction of a novel prognostic signature based on moonlighting genes in prostate cancer.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Procollagen-Lysine,2-Oxoglutarate 5-Dioxygenase 3 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.